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Abstract 
Insulinomas are rare, usually benign, solitary tumours 
accounting for 60% of islet cell tumours. These tumours can 
be difficult to localize preoperatively due to their small size. 
We present a challenging case of a 40 year old male with 
frequent hypoglycaemic spells and endogenous 
hypoglycaemia who presented as a diagnostic dilemma. 
Patient had an occult insulinoma with inconclusive CT 
Abdomen, MRI Abdomen and Octreotide scan. The final 
localization of the tumour was made by  selective arterial 
calcium stimulation testing (SCAT), done for the first time 
in Pakistan at Aga Khan University Hospital. This was 
followed by successful distal pancreatectomy as localizd by 
SACT yielding a well differentiated neuroendocrine tumour. 
After surgery patient made a robust recovery with no 
further hypoglycaemic symptoms. Hence successful 
localization and management of occult insulinomas can be 
challenging but can be achieved with the advent of newer 
invasive modalities. 




The first insulinoma was described by an orthopaedic 
surgeon, Wider and colleagues in 1927, who experienced 
frequent neuroglycopenic symptoms due to prolonged 
fasting in the operating room.1 Insulinomas are rare 
tumours with an incidence of 4 patients per 1 million /year 
and accounts for 60% of islet cell tumours.2 They are 
typically solitary tumours with 90% measuring less than 2 
cm. They can also present as a benign multicentric disease 
in patients with MEN 1.3 Due to their nonspecific, 
occasionally bizarre symptoms these tumours can disguise 
themselves with various neuropsychiatric conditions.4 An 
occult insulinoma refers to a biochemically proven tumour 
with an undetermined anatomical site before surgery.5 
Their small size and difficult preoperative localization along 
with nonspecific symptoms poses a diagnostic dilemma to 
both the endocrinologists and surgeons. We present a case 
of a 40 year old male with an occult insulinoma which after 
a rigorous but futile imaging work up was finally localized 
by Selective Calcium Arterial Stimulation Testing (SCAST), 
done first time in the history of Pakistan at Aga Khan 
University Hospital. The consent of the patient was taken 
prior to the manuscript writing. 
Case 
A 44 years old male known case of Hypothyroidism and 
Hypertension presented to our endocrine clinic for the first 
time in June 2017 with episodes of recurrent sweating, 
tremors, palpitations and generalized weakness. Patient 
had these symptoms since last 2 years, observed during 
fasting and relieved with food intake. During these 
episodes his glucose went down to 35 -40mg/dl. He 
combated with these spells of hypoglycaemia with instant 
intake of choclates or sugar but did not seek any 
professional help, due to excessive binge eating there was 
a noticeable weight gain over this two year period.  He had 
a past history of pulmonary tuberculosis, treated few years 
back. Family history was positive for diabetes, 
hypertension, coronary artery disease and breast 
carcinoma. His medication history included Olmesartan 40 
mg OD and thyroxine 150 mcg OD. His multiple Serum 
insulin, C- peptide, blood glucose done during 2 years 
period were clearly suggestive of endogenous 
hypoglycaemia. Patient had a BMI of 31.5kg/m2. Rest of his 
physical examination was unremarkable. On the basis of 
history and biochemical evaluation diagnosis of 
Spontaneous hypoglycaemia secondary to endogenous 
hyperinsulinaemic hypoglycaemia was made and patient 
was advised CT scan abdomen (Pancreatic protocol) which 
showed no pancreatic mass following which he was asked 
to get MRI abdomen as next line investigation which also 
did not reveal any pancreatic , hepatic or other masses. He 
then underwent Somatostatin receptor scintigraphy with 
no uptake in pancreas or liver. Patient was then planned for 
Angiography of Coeliac and Superior mesenteric arteries 
to look for tumour blush followed by Selective Calcium 
Arterial Stimulation Testing (SCAST). This test involved the 
femoral vein and artery cannulation with passage of a 
sampling catheter to the right hepatic vein for sampling of 
insulin and sequentially under fluoroscopic guidance, a 
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catheter placed into the splenic, superior mesenteric and 
gastroduodenal arteries to allow injection of calcium 
gluconate into these arteries. A positive response was 
defined as at least a doubling of the insulin level after 
injection calcium gluconate at more than one time point. 
SCAST with venous sampling after calcium infusion 
showed many folds increase in insulin, C peptide levels in 
the splenic artery thus pointing towards the culprit lesion 
in the body or tail of his pancreas (Table). Patient was then 
referred to an experienced surgeon with the plan of a 
pancreactic enucleation if the tumour could be localized 
on peroperative ultrasound otherwise distal pancreactomy 
being the second option. As the adenoma could not be 
localized on peroperative ultrasound therefore he 
underwent distal pancreatectomy. His histopathology 
report showed a well differentiated neuroendocrine 
tumour, grade 1 of distal pancreas with a size of 1.5X1.3 
cm, Ki-67 index of <2% and stage of pT1,Nx (figure). 
Postoperatively patient made good recovery with no 
further hypoglycaemic episodes on follow up after one 
month of his surgery and to date enjoying a healthy 
life. 
Patient was not evaluated for MEN1 as he denied any 
other symptoms besides hypoglycaemia, also his 
baseline work up did not show any clue of a 
concomitant illness. 
Discussion 
Insulinomas are rare tumours but among the 
functioning islet cell tumours are the most common. 
Patients usually present with fasting hypoglycaemia 
but upto 25% of such patients can also present with 
post prandial hypoglycaemia. The hypoglycaemic 
spells constitute both neuroglycopenic symptoms 
including confusion, visual change and unusual behaviour 
that may or may not be preceded by sympathoadrenal 
symptoms which includes tremulousness, palpitations or 
diaphoresis.6,7 The hypoglycaemia in insulinoma is 
observed to be due to reduced hepatic glucose output 
rather than an increased glucose utilization. In a study 
conducted at Mayo clinic it was observed that it took a 
median time of 1.5 years for a patient to report his 
symptoms before a diagnosis of insulinoma was made.2  
The biochemical diagnosis of insulinoma is established by 
demonstrating raised serum insulin and C- peptide levels 
during an episode of hypoglycaemia, but the diagnosis and 
preoperative localization of these occult tumours is never 
straight forward owing to the small size and sporadic 
distribution, thus it remains a diagnostic challenge to the 
endocrinologists, surgeons and the radiologists. Surgical 
removal is the treatment of choice in insulinomas,  
therefore it is imperative to localize these tumours 
preoperatively as it not only helps in deciding the type of 
surgery but also some of these tumours may not be 
palpable at the time of surgery. 
After biochemical confirmation preoperative procedures 
for tumour localization includes number of noninvasive 
and invasive radiological investigations most of which are 
operator dependent and require skills. These include 
transabdominal ultrasonography (sensitivity 30%-61%), CT 
(sensitivity 42%-78%), MRI Abdomen (sensitivity 20%-
100%), octreotide scan (sensitivity 78%-86%), Endoscopic 
ultrasonography (sensitivity 80%), Selective Arterial 
Calcium Stimulation Testing(SACST) with hepatic venous 
sampling(sensitivity 90%), and intraoperative 
Table: Selective Calcium Arterial Stimulation Test Results. 
Peripheral Hepatic Superior Mesenteric Gastroduodenal Splenic  
Artery Artery Artery Artery Artery 
0 sec:  
Preinjection Post 30 sec Post 30 sec Post 30 sec Post 30 sec 
Insulin 51.30 Insulin 48.80 Insulin 127.60 Insulin 139.10 Insulin >300 
C-peptide 7.32 C-peptide 6.13 C-peptide 9.06 C-peptide 12.90 C-peptide >20 
Post 60 sec Post 60 sec Post 60 sec Post 60 sec 
Insulin 55.30 Insulin 114.20 Insulin 144.00 Insulin >300 
C-peptide 6.73 C-peptide 9.68 C-peptide 9.46 C-peptide 17.50 
Post 90 sec Post 90 sec Post 90 sec Post 90 sec 
Insulin 63.40 Insulin 137.30 Insulin 127.60 Insulin >300 
C-peptide 7.29 C-peptide 9.17 C-peptide10.50 C-peptide 12.30 
Post 120 sec Post 120 sec Post 120 sec Post 120 sec 
Insulin 63.40 Insulin 128.10 Insulin 51.30 Insulin 214.60 
C-peptide 6.39 C-peptide 9.99 C-peptide 7.32 C-peptide 12.70 
Post 180 sec Post 180 sec Post 180 sec Post 180 sec 
Insulin 59.80 Insulin 105.80 Insulin 139.80 Insulin 149.80 
C-peptide 7.83 C-peptide 10.00 C-peptide 11.10 C-peptide 12.20
Figure: [A] Tumor cells showing round to oval, mildly pleomorphic nuclei with 
characteristic finely stippled (salt and pepper) chromatin and 
inconspicuouc nucleoli (H&E stain, 400x) [B] Tumour cell invading into 
pancreatic acini (arrows) (H&E stain, 400x) [C] Perineural invasion 
(arrows) (H&E stain, 400x) [D] Peripancreatic fat invasion (arrows)  
(H&E stain, 400x)
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ultrasonography (sensitivity 90%) with bimanual 
palpation.8 
Selective Arterial Calcium Stimulation Testing (SACST) is an 
interventional radiological technique. John L. Doppman9 
developed SACST after observing that intravenously 
administered calcium stimulates insulin release from from 
insulinoma, but not from normal beta cells . Placzkowski et 
al. demonstrated a sensitivity for localization of upto 93 % 
in patients who underwent this procedure in Mayo clinic 
series.6 
Literature review shows SACT to be superior to other non 
invasive modalities with localization sensitivity of 87.5 to 
90%.10 When compared with other invasive techniques like 
EUS, the localization sensitivity of EUS is similar to SACT but 
does not provide functional information with its specificity 
being affected when pancreatic nodularities are mistaken 
for insulinomas. The short comings of the two procedures 
are similar including invasiveness with lack of universal 
availability and operator and centre dependence.11 
SACT involves the arterial catheterization of arteries 
supplying the pancreas and injecting calcium gluconate 
which acts as the insulin secretagogue. The samples are 
then collected from the right hepatic vein before and after 
the calcium gluconate injection at different time intervals. 
The pancreatic artery showing the highest relative fold 
increase (two to four times) in hepatic venous insulin 
concentration over baseline following calcium stimulation 
is considered to be the dominant artery supplying the 
insulinoma.9 Preoperative localization of insulinoma can 
guide the surgeon to decide the extent of surgery. 
Since we did not have the availability of Endoscopic 
ultrasound facility in our center therefore Selective Arterial 
calcium Stimulation testing with hepatic venous sampling 
was considered an option for tumour localization .  
Despite its high sensitivity, the utility of SACT outside 
insulinoma diagnosis remains unkown. Similarly the 
diagnostic accuracy of this test also remains undetermined 
as this test is done on patients with a pre established 
diagnosis of insulinoma. The diagnostic accuracy of SACT 
was questioned with diffusely positive SACT response in 
cases of surreptious Repaglinide and sulfonylurea.12,13 
Important challenge in doing SCAST is having a centre 
equipped with interventional radiology services with 
Interventional radiologist able to interpret normal and 
abberant vascular anatomy since the anatomy of the 
coeliac axis and superior mesenteric artery is aberrant in 
approximately 40 percent of patients. Close 
communication between the endocrinologist,  
interventional radiologist and laboratory  is required to 
interpret the results correctly and manage the patient 
appropriately. 
Although being done in different countries this test was a 
new milestone in the endocrine history of Pakistan as it was 
the first time ever that this invasive technique was 
successfully attempted. Localizing the culprit insulin 
producing tumour by SACST open new doors, providing 
ground for other centers in Pakistan equipped with 
interventional radiology to start performing this test where 
diagnosing insulinoma remains a challenge pre operatively. 
Conclusion 
Insulinomas being rare intrapancreatic tumours can pose 
a diagnostic dilemma due to its difficult preoperative 
localization but with the advent of newer invasive 
modalities there has been a good yield in localizing them 
preoperatively and thus avoiding unnecessary total 
pancreatectomy. 
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